期刊文献+

血清癌胚抗原与非小细胞肺癌患者EGFR突变的关系及其对预后的影响 被引量:26

Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations and prognosis in resected non-small cell lung cancer
下载PDF
导出
摘要 目的:探讨血清癌胚抗原(CEA)水平与非小细胞肺癌患者EGFR基因突变的关系及预测价值,分析CEA水平对肺癌患者术后生存期的影响。方法:选取2009年3月至2011年3月于天津医科大学肿瘤医院肺部肿瘤科行外科手术治疗的患者387例,术前行CEA等肿瘤标志物检测,术后常规行EGFR基因突变检测,分析CEA等肿瘤标志物与EGFR突变关系及其与患者预后的关系。结果:全组患者中出现EGFR基因突变的患者共168例,突变阳性率43.4%,EGFR突变在女性、非吸烟、腺癌以及年龄〈60岁的患者中更加常见(P〈0.05),另发现EGFR突变情况与肿瘤标志物及化疗敏感性指标相关,EGFR野生型患者的Cyfra21-1、SCC升高、ERCC1阳性表达更常见(P〈0.05),而EGFR基因突变患者的CEA升高则更常见(P=0.015),并且随着CEA水平的升高,EGFR基因突变阳性率更高(血清CEA水平〈5μg/L、5~20μg/L及〉20μg/L 3组的阳性率分别为40.1%、47.5%和66.6%,P=0.003)。Logistic回归分析发现CEA水平是预测EGFR基因突变的独立因素,并且血清CEA水平也是影响非小细胞肺癌患者预后的独立因素(CEA水平升高组与正常组2年生存率分别为75.9%和88.4%,P〈0.01)。结论:血清CEA水平高低可以预测手术切除的非小细胞肺癌患者的预后,并且与非小细胞患者EGFR突变相关,可以初步指导EGFR突变情况。 Objective:To investigate the relationship between serum carcinoembryonic antigen (CEA) and the predictive value of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer patients, as well as to analyze further EGFR muta-tions and CEA levels affecting patient survival. Methods:From March 2009 to March 2011, a total of 387 cases were treated in the Lung Cancer Department in Tianjin Cancer Hospital. Preoperative CEA tumor marker and postoperative EGFR gene mutation were used for routine detection. The influence of CEA tumor marker on EGFR mutation and its relationship with the prognosis were ana-lyzed further. Results:A total of 168 cases involved EGFR mutations, the incidence of which is more frequent in women, non-smokers, adenocarcinoma patients, and patients below 60 years old (P〈0.05). This study also determined that EGFR mutation was related with tu-mor markers and chemosensitivity indicators. Elevated Cyfra21-1, SCC, and ERCC1-positive are more common in wild-type patients (P〈0.05). However, abnormal CEA was more common in EGFR mutation patients (P=0.015). The rate of EGFR gene mutations signifi-cantly increased as the serum CEA level increased. Serum CEA levels were divided into three groups (〈5, 5-20, and〉20). The positive rates of EGFR mutations were 40.1%, 47.5%and 66.6%(P=0.003). Logistic regression analysis determined that CEA levels are inde-pendent factors in predicting EGFR mutations and independent prognostic factors in patients with non-small cell lung cancer. Conclu-sion:Serum CEA levels can independently predict the prognosis of resected non-small cell lung cancer patients, which is has a close re-lationship with EGFR mutations.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2014年第17期1075-1079,共5页 Chinese Journal of Clinical Oncology
关键词 非小细胞肺癌 EGFR CEA手术切除 预后 non-small cell lung cancer, EGFR, CEA, resection, prognosis
  • 相关文献

参考文献16

  • 1Pan 0. Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas[J].J Mol Diagn, 2005, 7(3):396-403.
  • 2Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Science[J]. N Engl J Med, 2004, 350(21):2129-2139.
  • 3Paez JG, Jnne PA, LeeJC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500.
  • 4Shepherd FA, Rodrigues Pereira j, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005, 353(2):123-132.
  • 5Douillard JY, Laporte S, Fossella F, et al. Comparison of docetax- el- and vinca alkaloid-based chemotherapy in the first-line treat-ment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials[J]. J Thorac Oncol, 2007, 2(10): 939-946.
  • 6Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutation are common in lung cancers from"never smokers"and are associat- ed with sensitivity of tumors to gefitinib and erlotinib[]]. Proc Nat Acad Sci U S A, 2004, 101(36):13306-13311.
  • 7Zhao LD, Li JL, Wang Y, et al. Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-smaU cell lung cancer[J]. Zhonghua Zhong Liu Za Zhi, 2011, 33(3):217-221.
  • 8Won YW, HanJY, Lee GK, et al. Comparison of clinical outcome of patients with non-small--ceU lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations[]]. J Clin Pathol, 2011, 64(11):947-952.
  • 9Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WfFOG3405): an open label, randomised phase 3 triM[J]. Lancet Oncol, 2010, 11(2): 121-128.
  • 10Rosell R, Moran T, Carcereny E, et al. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain[]]. Clin Transl Oncol, 2010, 12(2):75-80.

同被引文献187

  • 1高亚维,哈敏文.CIP2A在非小细胞肺癌的表达及患者预后分析[J].中国生化药物杂志,2014,34(4):81-84. 被引量:2
  • 2王敬慧,张树才,刘志东,陈效友,李传友,韩毅马.肺癌患者外周血癌胚抗原、细胞角蛋白19 mRNA表达水平与肿瘤分期、近期疗效及预后的关系[J].中华结核和呼吸杂志,2005,28(11):773-776. 被引量:8
  • 3曹杰,李旺林,杜洪,唐伟镖,王辉.FHIT和p53在结肠癌中的表达及其意义[J].中华实验外科杂志,2006,23(7):787-788. 被引量:16
  • 4邵明海,陈仕林,卢洪胜,周涛,王碧云.胸腺瘤WHO组织学分型、Masaoka临床分期和预后的关系[J].实用肿瘤学杂志,2007,21(2):128-130. 被引量:10
  • 5Toyokawa G, Takenoyama M, Ichinose Y, et al.Multimodality treatment with surgery for locally advanced non-small=cell lung cancer with N2 disease: a review article[J].Clinical Lung Cancer, 2014, 16 (I): 6-14.
  • 6Raymond H M, Hermann G, John H L, et al.Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-celliung cancer[J].Clinical Lung Cancer, 2015, 16 ( 1) : 24-32.
  • 7Hinitt CAM, Wood 1. Lee S S, et al.BAG-I enhances cell- cell adhesion, reduces proliferation and induces chaperone-independent suppression of hepatocyte growth factor-induced epidermal keratinocyte migrationl Ij.Experimental Cell Research, 2010, 316 ( 13 ) : 2042-2060.
  • 8Eguchi K, Oyama T, Tajima A, et al.Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan[J].Lung Cancer, 2015, 87 ( 1 ) : 53-58.
  • 9Takenaka T, Takenoyama M, Toyozawa R, et al.Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung ceucerl Jj.Clinical Lung Cancer, 2015, 16 ( 1 ) : 51-56.
  • 10Hattori Y, Satouchi M, Shimada T, et al.A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor ( EGFR ) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109 ) [J].Lung Cancer, 2015, 87 (2) : 136-140 .

引证文献26

二级引证文献187

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部